Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ZGN-1061 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| 0.05 mg ZGN-1061 (A) | EXPERIMENTAL | 0.05 mg ZGN-1061 subcutaneous injection once every 3 days |
| 0.3 mg ZGN-1061 (B) | EXPERIMENTAL | 0.3 mg ZGN-1061 subcutaneous injection once every 3 days |
| 0.9 mg ZGN-1061 (C) | EXPERIMENTAL | 0.9 mg ZGN-1061 subcutaneous injection once every 3 days |
| 1.8 mg ZGN-1061 (CC) | EXPERIMENTAL | 1.8 mg ZGN-1061 subcutaneous injection once every 3 days |
| Placebo (D) | PLACEBO_COMPARATOR | Placebo subcutaneous injection once every 3 days |
| Name | Type | Description |
|---|---|---|
| ZGN-1061 | DRUG | ZGN-1061 is a methionine aminopeptidase 2 inhibitor |
| Placebo | DRUG | Placebo has the same excipients and appearance as ZGN-1061 |
Inclusion Criteria: Subjects must meet the following criteria to participate in this study: * Be between the ages of 18 and 70 years, inclusive. * Overweight or obese with a body mass index of at least 27 kg/m². * Have type 2 diabetes with HbA1c between 7% and 11%. * For subjects taking approved a...
ZGN-1061 is an investigational small molecule being developed for the treatment of Type 2 Diabetes Mellitus. It is being studied in overweight and obese participants with Type 2 Diabetes. The drug is in Phase 2 clinical development and is not yet approved by regulatory authorities.
ZGN-1061 is being developed by Larimar Therapeutics, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol LRMR. The company is conducting clinical trials to evaluate the drug's effects and safety in patients with Type 2 Diabetes Mellitus.
ZGN-1061 is in Phase 2 clinical development. A Phase 2 trial has been completed, and the drug remains investigational. It has not been approved by the FDA or any other regulatory agency, and its safety and efficacy are still being evaluated in clinical studies.
ZGN-1061 has one completed Phase 2 clinical trial, registered under NCT03254368. The study assessed the effects and safety of ZGN-1061 in overweight and obese participants with Type 2 Diabetes. The trial enrolled 188 participants and was conducted in Australia and New Zealand.
ZGN-1061 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development. A Phase 2 trial has been completed, but the drug has not yet received marketing approval from the FDA or other regulatory bodies.
The completed Phase 2 trial for ZGN-1061 was a randomized, double-blind, placebo-controlled study. It enrolled 188 participants with Type 2 Diabetes Mellitus who were overweight or obese. The trial was conducted at sites in Australia and New Zealand and included adults aged 18 years and older.